14th week of 2011 patent applcation highlights part 20 |
Patent application number | Title | Published |
20110081292 | Methods Of Treating Viral Hepatitis - Disclosed are methods of treating viral hepatitis including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed. | 2011-04-07 |
20110081293 | METHODS AND COMPOSITIONS RELATED TO CLOT-BINDING LIPID COMPOUNDS - Disclosed are compositions and methods related to clot-binding head groups. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | 2011-04-07 |
20110081294 | CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING AND PHOTOACOUSTIC IMAGING METHOD - A method of detecting a contrast agent for photoacoustic imaging provides a high signal intensity. In a contrast agent for photoacoustic imaging, each particle containing an inorganic material supports at least an organic dye having an absorption coefficient in the near infrared region by means of chemical bonding. | 2011-04-07 |
20110081295 | PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR EXPRESSION LEVEL AS AN INDEX OF ORGAN DAMAGE AND REGENERATION - The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy. | 2011-04-07 |
20110081296 | SYSTEMS AND METHODS FOR IDENTIFICATION OF CILIOPATHY THERAPEUTICS - The invention provides systems and methods for identifying therapeutic targets for treating a disease including a ciliopathy. The invention further provides for drug discovery, and animal model systems related to drug discovery. The invention further relates to therapy of genetic disorders of the cellular cilia or basal bodies. | 2011-04-07 |
20110081297 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles - The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and processes for making such compounds. | 2011-04-07 |
20110081298 | RATIOMETRIC BIOLUMINESCENT SENSOR FOR IMAGINING OXIDATIVE STRESS - This invention provides a novel ratiometric bioluminescent sensor and methods of use thereof. The bioluminescent sensor comprises two luminescent proteins that exhibit different characteristics associated a biological condition, and thereby illuminates differently in response to the biological condition. A ratio between the luminescence of the two luminescent proteins indicates a change in the biological condition. The bioluminescent sensor of the invention can be used to image an oxidative stress or its associated conditions, including a programmed cell death. | 2011-04-07 |
20110081299 | CLEANING AND DISINFECTING AGENT - A detergent and disinfectant in which water-soluble permanganates are used in an alkaline solution in order to initiate the oxidation of organic substances and simultaneously a chemical oxidant, preferably a peroxodisulfate, is used which is capable of producing radical reactions with catalytic support by manganates originating from the supplied permanganate, which reactions produce the oxidation of organic substances. All components are present in powder form and a respective powder mixture can be dissolved rapidly and free from residues in water. It thus represents a universally applicable, highly effective detergent and disinfectant. | 2011-04-07 |
20110081300 | Methods and composition for treating a material - A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. Also described are methods of making the composition. | 2011-04-07 |
20110081301 | PHARMACEUTICAL AEROSOL FORMULATIONS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE - Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurised metered dose inhalers (pMDIs). | 2011-04-07 |
20110081302 | PROCESS FOR THE OBTENTION OF PURIFIED HEPTAFLUOROPROPANE - Process for the obtention of HFC-227ea having a reduced content of organic impurities, comprising at least subjecting a crude HPC-227ea to two distillation steps at different pressures. | 2011-04-07 |
20110081303 | TEETH CLEANING COMPOUND CONTAINING MENTHOL WITH REDUCED BITTER SENSATION - The present invention primarily concerns teeth cleaning compounds containing menthol for use with a toothbrush, preferably tooth pastes, tooth crèmes, tooth cleaning gels or tooth powders. Such a tooth cleaning compound according to the invention contains menthol and a quantity, for masking the bitterness of the menthol, of menthane carboxylic acid-N-(4-methoxyphenyl)-amide (WS-12) of the following formula (Ia), in particular of the following formula (Ib), i.e. L-menthane carboxylic acid-N-(4-methoxyphenyl)-amide. | 2011-04-07 |
20110081304 | EXTRACTS OF PHYLLANTHUS NIRURI - A method of making a low molecular weight fraction of | 2011-04-07 |
20110081305 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT - The present invention relates to a composition comprising a skin-lightening resorcinol and a skin darkening agent. The composition may be topically applied to the skin, such as to treat signs of aging. | 2011-04-07 |
20110081306 | REMOVABLE COLOR LAYER FOR ARTIFICIAL NAIL COATINGS AND METHODS THEREFORE - The present disclosure relates to a nail coating system comprising a basecoat, a color layer, and a topcoat. The system of the present disclosure may be applied to natural and/or pre-existing artificial nail coatings. The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but not by way of limitation, to polymerizable compositions and color layers polymerized therefrom. The disclosure further relates to methods of making a polymerized color layer. | 2011-04-07 |
20110081307 | KIT COMPRISING AN ALGINATE AND A COMPLEXING AGENT IN THE FORM OF A WATER-SOLUBLE SALT - The present patent application relates to a keratin material coating kit comprising: a first composition comprising an aqueous phase, at least one alginic acid-based compound A and at least one compound B in the form of a water-soluble salt, the said compound being capable of releasing a gas on contact with an acid having a pKa ranging from 1 to 6, and a second composition comprising at least one acid having a pKa ranging from 1 to 6 and at least one agent C for complexing the alginic acid-based compound, the said agent being in the form of a water-soluble salt. | 2011-04-07 |
20110081308 | EXTRACTS OF PHYLLANTHUS NIRURI - A method of making a low molecular weight fraction of | 2011-04-07 |
20110081309 | COMPOSITIONS COMPRISING A SUPERHYDROPHILIC AMPHIPHILIC COPOLYMER AND A MICELLAR THICKENER - Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer, a micellar thickener, and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating a mammal by applying healthcare compositions of the present inventions to the mammalian body. | 2011-04-07 |
20110081310 | COMPOSITIONS COMPRISING SUPERHYDROPHILIC AMPHIPHILIC COPOLYMERS AND METHODS OF USE THEREOF - Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating the human body by applying healthcare compositions of the present inventions to the body. | 2011-04-07 |
20110081311 | COMPLEXES OF IL-15 AND IL-15RALPHA AND USES THEREOF - The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol″ those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-β-1-♦4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function. | 2011-04-07 |
20110081312 | 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-Y- LIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE) - An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid. | 2011-04-07 |
20110081313 | MECHANISM OF ACTION OF PRIMARY CELL DERIVED BIOLOGIC - A method of treating an immune target that is suppressing the immune system and restoring the immune system, including the steps of administering an effective amount of a primary cell derived biologic, modifying populations of B and T cells in blood, activating regional lymph nodes, infiltrating an area adjacent to an immune target with T helper and B cells, infiltrating the immune target with T killer cells and macrophages, and treating the immune target and restoring the immune system. A method of inducing immunization in a patient. A method of destroying a tumor. A method of predicting a favorable treatment outcome to cancer treatment. A method of immune prophylaxis. A method of immune restoration. A method of treating a tumor. A method of preventing tumor escape. | 2011-04-07 |
20110081314 | ANTIVIRAL PHOSPHINATE COMPOUNDS - The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2011-04-07 |
20110081315 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2011-04-07 |
20110081316 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2011-04-07 |
20110081317 | Enhancing Gene Transfer - Described herein are methods of improving the efficiency of gene transfer for a wide range of applications. Specifically provided are methods of increasing expression of an exogenous gene in a cell by contacting the cell with a vector comprising the exogenous gene and contacting the cell with a proteasome inhibitor, a lysosomal protease inhibitor and/or a microtubule inhibitor. Also provided are methods of delivering an antigen delivery vector to a cell or a subject. Provided are antigen delivery systems and kits comprising an antigen delivery vector and a proteasome inhibitor, a lysosomal protease and/or a microtuhulc inhibitor. | 2011-04-07 |
20110081318 | VIRAL COMPOSITIONS AND METHODS - Methods for producing recombinant viruses, compositions including the viruses, and uses for the compositions are described herein. | 2011-04-07 |
20110081319 | COMPOSITION AND USE OF PHYTO-PERCOLATE FOR TREATMENT OF DISEASE - This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme having proteolytic activity. The invention further relates to the use of the phyto-percolate in a variety of disease state. | 2011-04-07 |
20110081320 | Treatment/Cure of Autoimmune Disease - An embodiment entails administering an effective amount of a product such as a protease or a source of a protease that destroys or deactivates an immunogen, mimic or antigen specific to a particular autoimmune disease before it encounters the immune system of a patient. | 2011-04-07 |
20110081321 | OMENTUM AS A SOURCE OF STROMAL/STEM CELLS AND MEDICAL TREATMENTS USING STROMAL/STEM CELLS - Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue fibrosis. According to one aspect, a medical procedure is performed on a patient that involves harvesting omental tissue from the patient, and then transferring the omental tissue to an organ of the patient. At least a portion of the harvested omental tissue may be activated prior to transferring the omental tissue to the organ. Alternatively, the transferred omental tissue may comprise non-lymphoid cells isolated from the omentum tissue and obtained by homogenizing at least a portion of the harvested omental tissue. The invention also encompasses a medical procedure comprising the transfer of omental stem cells to a patient, and a procedure comprising in vitro activation of omental stem cells by T cells to enhance immunomodulatory functions of the omental stem cells. | 2011-04-07 |
20110081322 | ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME - The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention. | 2011-04-07 |
20110081323 | Methods and compositions for organ and tissue functionality - Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described. | 2011-04-07 |
20110081324 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR - Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes, as drug delivery vehicles and in delivering populations of cells to a site of disease or injury. | 2011-04-07 |
20110081325 | NOVEL TREATMENT OF HEART DISEASES - Provided is a novel therapeutic approach for the treatment of heart failure and diseases associated therewith. In particular, vinca alkaloids are used for improving the viability of cardiomyocytes and preventing myocardial infarction. | 2011-04-07 |
20110081326 | DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing. | 2011-04-07 |
20110081327 | TRANSIENT EXPRESSION OF IMMUNOMODULATORY POLYPEPTIDES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE, ALLERGY AND TRANSPLANT REJECTION - A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an IFN-α receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions. | 2011-04-07 |
20110081328 | Use of selected lactic acid bacteria for reducing atherosclerosis - Strains of lactic acid bacteria selected for their capability of increasing the BSH-activity and consequently lowering serum LDL-cholesterol, and simultaneously decreasing the pro-inflammatory cytokine TNF-α levels, for prophylaxis and/or treatment of atherosclerosis and other cardiovascular diseases, a method of selecting such strains, and products containing such strains. | 2011-04-07 |
20110081329 | AMINO ACID COMPOSITIONS - Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanie, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histindine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia. | 2011-04-07 |
20110081330 | COMPOSITIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS CONTAINING GUM GHATTI - The present invention relates to compositions containing plant gums and one or more fat-soluble active ingredients, wherein the composition comprises less than 40 weight-% oil, based on the total composition in dry matter. These compositions can be used for the enrichment, fortification and/or coloration of food beverages, animal feed, cosmetics or pharmaceutical compositions. The present invention also refers to the preparation of such compositions. The present invention furthermore refers to a process for the manufacture of a beverage by mixing the compositions with ingredients of beverages. The present invention also refers to beverages obtainable by this process. | 2011-04-07 |
20110081331 | CANCER THERAPY - The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein. | 2011-04-07 |
20110081332 | TREATMENT OF NON-ALCOHOLIC STEATOTIC HEPATITIS (NASH) - The present invention relates to a method for treating non-alcoholic steatotic hepatitis (NASH) in a subject by administering an effective amount of a lipoprotein lipase (LPL) therapeutic to the subject. The LPL therapeutic is advantageously a S447X protein or a derivative or variant thereof, or a nucleic acid encoding such a protein. The LPL therapeutic may be used in a gene therapy vector. | 2011-04-07 |
20110081333 | APPARATUS AND SYSTEM FOR TREATMENT AND PREVENTION OF BAGS UNDER EYES - A simple, safe and effective invention devices for treating bags under the eyes pressure exerting glasses devices, compress badges, bag pressure adhesive strips, cosmetic pressure adhesive strips; to be put on to prevent, and to reduce the bags under the eyes. They are designed to apply antiwrinkle and other cosmetic and therapeutic agents such as hormones, known therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals and biological agents, or compounds to enhance the health and beauty of the eye, strengthen the lower eye lids and to treat many oculopathies which can contribute to the condition. They can be used for the eye makeup cosmetically as adjuvant to eye makeup. The electrical stimulation and electromotive force are incorporated in the invention to strengthen the lower eye lids muscles, to improve the health of the eye lids skin and for the delivery of therapeutic agents to treat various oculopathies. | 2011-04-07 |
20110081334 | C1-Inhibitor Prevents Non-Specific Plasminogen Activation by a Prourokinase Mutant without Impeding Fibrin-Specific Fibrinolysis - A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis. Methods of reducing bleeding and non-specific plasminogen activation during fibrinolysis by administering M5 along with exogenous C1-inhibitor are disclosed. | 2011-04-07 |
20110081335 | PROCESSING BIOMASS - Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids. | 2011-04-07 |
20110081336 | PROCESSING BIOMASS - Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids. | 2011-04-07 |
20110081337 | FUNCTION OF GPR4 IN VASCULAR INFLAMMATORY RESPONSE TO ACIDOSIS AND RELATED METHODS - The present invention relates to methods for the treatment of inflammation. Specifically, disclosed herein are methods to inhibit vascular inflammatory responses by inhibiting the proton-sensing GPR4 receptor. Such methods can be utilized, most preferably, in pharmaceutical compositions to modulate inflammation in acidosis-related diseases. | 2011-04-07 |
20110081338 | METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION - The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals. | 2011-04-07 |
20110081339 | METHODS OF USING IL-17 RECEPTOR A ANTIBODIES - The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation. | 2011-04-07 |
20110081340 | METHODS FOR TREATING DISEASE USING AN ANTI-IL-21 RECEPTOR ANTIBODY - Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response. | 2011-04-07 |
20110081341 | IMMUNOPOTENTIATIVE COMPOSITION - Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection. | 2011-04-07 |
20110081342 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 2011-04-07 |
20110081343 | VACCINES DIRECTED TO LANGERHANS CELLS - The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use. | 2011-04-07 |
20110081344 | SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2011-04-07 |
20110081345 | SINGLE CHAIN FC, METHODS OF MAKING AND METHODS OF TREATMENT - The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule. Binding entities can be fused to the scFc molecule in a variety of configurations. The present invention also relates generally to methods for making such molecules and methods for their use. The scFc molecules provided herein can be recombinantly produced. Also provided are monovalent forms of the scFc molecules that have an equivalent or superior ADCC and/or CDC response than do bivalent molecules targeting the same antigens. Provided herein are improved antigen binding compositions. Methods for using the scFc molecules of the present inventions are provided | 2011-04-07 |
20110081346 | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS - Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells. | 2011-04-07 |
20110081347 | Antibodies with Altered Binding to FcRn and Methods of Using Same - This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 2011-04-07 |
20110081348 | FUNGAL SIGNALLING AND METABOLIC ENZYMES - Method of identifying an anti-fungal agent which targets as an essential protein or gene of a fungus comprising contacting a candidate substance with (i) a protein which comprises the sequence shown by SEQ ID NOS: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 50, 53, 56, 59, 61 or 63, or (ii) a protein which has 60% identity with (i), or (iii) a protein comprising a fragment of (i) or (ii) which fragment has a length of at least 50 amino acids, or (iv) a polynucleotide that comprises a sequence which encodes (i), (ii) or (iii), or (v) a polynucleotide comprising a sequence which has at least 70% identity with the coding sequence of (iv), and determining whether the candidate substance binds or modulates (i), (ii), (iii), (iv), or (v), wherein binding or modulation of (i), (ii), (iii), (iv), or (v) indicates that the candidate substance is an anti-fungal agent. | 2011-04-07 |
20110081349 | ALLERGENIC LATEX PROTEIN - The present invention relates to a protein found in natural rubber that can induce an allergic reaction in persons who have been sensitised to it. The invention provides for the process of isolating and purifying the protein and describes the characteristics of the protein, including its molecular weight, isoelectric point, amino acid sequence and allergenicity. The invention also describes the isolation and cloning a the DNA that encodes the protein. The production of the recombinant version of the protein using a protein expression vector is described. | 2011-04-07 |
20110081350 | Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions - The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin V | 2011-04-07 |
20110081351 | ANTIHUMAN BAFF ANTIBODY - An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody. | 2011-04-07 |
20110081352 | IMMUNOGENIC PEPTIDES AND METHODS OF USE FOR TREATING AND PREVENTING CANCER - Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4 | 2011-04-07 |
20110081353 | ANTIBODY AGAINST THE CSF-1 R - The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions. | 2011-04-07 |
20110081354 | ANTI-CTLA-4 ANTIBODIES WITH REDUCED BLOCKING OF BINDING OF CTLA-4 TO B7 AND USES THEREOF - The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention. | 2011-04-07 |
20110081355 | Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies - Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma. | 2011-04-07 |
20110081356 | ANTI-CANCER DRUG - The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody. | 2011-04-07 |
20110081357 | Chimeric Vaccine for Haemophilus Influenzae-Induced Disease - The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention. | 2011-04-07 |
20110081358 | ANTIGENIC COMPLEX FOR THE DIAGNOSIS AND TREATMENT OF PORPHYROMONAS GINGIVALIS INFECTION - The present invention provides a purified multimeric complex from | 2011-04-07 |
20110081359 | Alpha 5 beta 1 and its ability to regulate the cell survival pathway - The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin α5β1. Most of the FGF-2-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Using function-blocking antibodies and peptides, a specific contribution of α5β1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated. The present invention thus allows for methods, agents and pharmaceutical compositions that can be used to potentiate the activity of chemotherapy or radiation therapy. | 2011-04-07 |
20110081360 | Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies. | 2011-04-07 |
20110081361 | ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR - The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities. | 2011-04-07 |
20110081362 | TREATMENT OF CANCER - Described herein are methods based, in part, on the discovery of genes or gene products that can be down-modulated to inhibit the growth and survival of a cell, such as a cancer cell. In one embodiment, the genes or gene targets are preferentially expressed in a cell having an activating Ras mutation (e.g., a cancer cell), which permits selective inhibition of growth in cells bearing an activating Ras mutation without affecting cells lacking enhanced Ras activity. In addition, the methods described herein provide for determining cancer prognosis in an individual bearing an activating Ras mutation. | 2011-04-07 |
20110081363 | COMPOSITIONS AND METHODS FOR BIOLOGICAL SAMPLE STORAGE - Compositions and methods are disclosed for substantially dry storage at ambient or elevated temperatures of biological samples such as nucleic acids, proteins and cells in a form from which the samples can be substantially recovered, using a dissolvable or dissociable dry storage matrix comprising a borate composition and a stabilizer as disclosed, such as any of a number of zwitterionic stabilizers. | 2011-04-07 |
20110081364 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of Aurora protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2011-04-07 |
20110081365 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X | 2011-04-07 |
20110081366 | IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES - Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant. | 2011-04-07 |
20110081367 | INFLUENZA SEQUENCES - We provide a nucleic acid sequence as shown in Table D1 or Table D2, or a variant, homologue, derivative or fragment thereof. A combination of two or more sequences is also provided. The nucleic acid sequence or combination may be used for detection of influenza or discrimination between strains of influenza. | 2011-04-07 |
20110081368 | Protein vaccines against poxviruses - The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins. | 2011-04-07 |
20110081369 | IMMUNE MODULATION WITH DEATH RECEPTOR-INDUCED APOPTOSIS - This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention. | 2011-04-07 |
20110081370 | Methods and Compositions for Modulating Immune Tolerance - The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection. | 2011-04-07 |
20110081371 | Angiotensin peptide-carrier conjugates and uses thereof - The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system. | 2011-04-07 |
20110081372 | Cosmetic Compositions And Container Therefor - A self-standing container holds particles of a cosmetic composition. The container may be cup-shaped or box-shaped, for example, and made of laminated paper or polystyrene. When ready to use, the user opens the container and adds liquid or gel to mix with the dry particles to form a moist cosmetic composition, so no separate mixing container or measuring cup is necessary. The composition formed is suitable for treating a user's skin and/or hair. A fill mark on the container informs the user of a proper amount of the liquid or gel to add to the container. The particles may include both ground-up and whole particles from substances such as dried botanicals (plant ingredients) and a binding agent. A cosmetic composition includes a ready-to-mix mixture of ingredients including particles from dried herbs and/or flowers and a dried food, and an essential oil. | 2011-04-07 |
20110081373 | ATTENUATING MUTATIONS IN THE INFLUENZA A VIRUS NEP(=NS2) PROTEIN - The invention provides an isolated attenuated recombinant influenza virus comprising a gene segment comprising a mutant NS2 protein gene, wherein the NS2 protein has at least two substitutions that do not substantially alter the in vitro replication of the virus but are associated with attenuation of the virus in vivo, wherein at least one of the substitutions is a substitution for glutamate. | 2011-04-07 |
20110081374 | RECOMBINANT AVIAN PARAMYXOVIRUS VACCINE AND METHOD FOR MAKING AND USING THEREOF - The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV. | 2011-04-07 |
20110081375 | CHIMERIC ADENOVIRAL VECTORS - The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest. | 2011-04-07 |
20110081376 | METHOD FOR USING INACTIVATED JAPANESE ENCEPHALITIS VIRUS PARTICLES AS ADJUVANT - A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method. | 2011-04-07 |
20110081377 | AEROSOLIZED GENETIC VACCINES AND METHODS OF USE - The present invention generally features methods for the mucosal delivery of immunogenic compositions and methods for treating or preventing diseases featuring such immunogenic compositions. In particular embodiments, the immunogenic compositions are genetic vaccines formulated as aerosols. | 2011-04-07 |
20110081378 | COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS - Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle. | 2011-04-07 |
20110081379 | PURIFICATION METHOD AND METHOD OF PRODUCING VACCINE - A method of purifying a virus or viral antigen from a sample solution containing the virus or viral antigen is provided. The method comprises: preparing sintered powder of hydroxyapatite, wherein a specific surface area of particles of the sintered powder is in the range of 2.0 to 11.0 m | 2011-04-07 |
20110081380 | Stabilizing Excipient for Inactivated Whole Virus Vaccine - The invention relates to a vaccine composition comprising:
| 2011-04-07 |
20110081381 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 2011-04-07 |
20110081382 | TREATMENT AND PREVENTION OF TUBERCULOSIS - The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related diseases. The composition useful for these purposes is disclosed, including the methods of using said composition. | 2011-04-07 |
20110081383 | LIVE ATTENUATED LEISHMANIA VACCINES - Targeted disruption of the centrin gene leads to attenuation of growth in the | 2011-04-07 |
20110081384 | METHODS OF WOUND CARE AND TREATMENT - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2011-04-07 |
20110081385 | Compositions and Methods for Sleep Regulation - Compositions and methods for the regulation of sleep and circadian rhythms are provided. The compositions are nutritional supplements containing melatonin and one or more vitamins that enhance the effectiveness of melatonin. Preferred vitamins include folic acid, riboflavin (vitamin B | 2011-04-07 |
20110081386 | CONTROLLED RELEASE OF ACTIVE AGENTS FROM OLEOSOMES - The release rate of an active agent from oleosomes can be modulated by formulation of the oleosomes with a release control agent, such as a multihydric alcohol. In this context, oleosomes containing an active agent may be used in the preparation of a variety of formulations, including formulations for topical use. | 2011-04-07 |
20110081387 | LIPOSOMES ENCAPSULATING AN OXAZOLIDIN-2-ONE COMPOUND - The invention is directed to liposomes comprising at least one wall formed by a bilayer of amphiphilic lipids and containing an oxazolidin-2-one compound substituted in the 4-position, of formula (I): | 2011-04-07 |
20110081388 | Detergent Composition - A detergent composition having from 1% to 50% by weight of anionic surfactant and from 0.1% to 30% by weight of sudsing particles. The sudsing particles have: an average per number length of from 50 nm to 50 μm, an average per number width of from 1 nm to 500 nm, an average per number ratio length/width from 1.5 to 1000, and an hydrophobicity measured by contact angle in the range of from 30° to 100°. The weight ratio of the total amount of anionic surfactant to the total amount of sudsing particles is from 0.05 to 20. | 2011-04-07 |
20110081389 | COMPOSITION COMPRISING A MIXTURE OF ACTIVE PRINCIPLES, AND METHOD OF PREPARATION - Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature. | 2011-04-07 |
20110081390 | Anhydrous, Transfer-Resistant Cosmetic Lip Compositions - The anhydrous cosmetic compositions of the present invention provide a durable film after application that resists degradation over time. The anhydrous cosmetic composition includes an aminosilicone, an organosiloxane resin, and a volatile carrier. The anhydrous cosmetic composition can also be packaged with a topcoat product. | 2011-04-07 |
20110081391 | SKIN-COVERING SHEET FOR IMPREGNATION WITH COSMETIC PREPARATION AND FACE MASK - A skin-covering sheet for impregnation with a cosmetic preparation according to the present invention includes a non-woven fabric in which a splittable conjugate fiber containing at least two components as viewed in fiber cross-section, namely a polyethylene component and another polymer component, and a hydrophilic fiber are blended, and hydroentangled. The conjugate fiber is partially split and includes a polyethylene ultrafine fiber having a fineness of | 2011-04-07 |